Prove the merits to improve the prospects!
Chronicle Pharmabiz
|November 27, 2025
MORE than a decade and a half has gone since introduction of the Pharm. D course in India.
About 10 batches of students have completed the 6 years course and are roaming in India in search of suitable jobs. Pharmacy Council of India which has introduced the course with much fanfare seems to have washed its hands! There is still resistance or reluctance from the doctors to appoint these Pharm.
Ds as clinical pharmacists in our hospitals.
Doctor's apprehension
When a principal approached a big hospital to provide training for Pharm. D students, its chief doctor put forth the first condition that Pharm. Ds should not criticize doctor's prescription! We should understand that apprehension.
Nobody likes to be criticized, especially in front of their customers. Hence Pharm. Ds should take a pledge first, not to hurt the feelings of doctors for that matter, all the colleagues in the hospital. Such lessons and training are given to Pharm. D students, even then there is disbelief among the doctors, that's why the conditions as above. It may take some time to vanish, after the introduction of clinical pharmacy services in our hospitals. Thus Pharm. Ds should be aware of what is preventing their entry as clinical pharmacists.
Other concerns
Few other issues with the doctors are the prestige, ego and superiority complex with them.
They think if clinical pharmacists are appointed in words they may lose their importance and respect. To overcome such problems, a clinical pharmacist should play only second or third fiddle to a doctor as a subordinate assistant. Only by such behaviour can they lay their way. As of now there is no motorable, why, even walkable road ahead. First generation Indian clinical pharmacists have that great responsibility before them to make a way by tolerating the thorns and stones while laying the road.
How to do that?
Cette histoire est tirée de l'édition November 27, 2025 de Chronicle Pharmabiz.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Chronicle Pharmabiz
Chronicle Pharmabiz
US FDA fortifies alliance with Telangana DCA
A high-level delegation from the US FDA concluded a significant meeting with the DCA in Telangana, two days ago, at the DCA office in Hyderabad.
2 mins
December 11, 2025
Chronicle Pharmabiz
India exploring possibilities to expand WHO standards for Indian medicines
INDIA is looking at possibilities to expand the World Health Organisation (WHO) global benchmarking standards for medicines, in order to unify and strengthen the drug regulatory mechanism for safety, quality and efficacy of medicines sold in the country.
1 min
December 11, 2025
Chronicle Pharmabiz
Eli Lilly gets US FDA approval for Jaypirca
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor.
1 mins
December 11, 2025
Chronicle Pharmabiz
Haryana DCA focuses on quality overhaul
THE Haryana drug control administration (DCA) is undertaking a major organizational overhaul focused on quality system upgrades and regulatory capacity building, particularly in response to the revised Schedule M norms.
2 mins
December 11, 2025
Chronicle Pharmabiz
DoC seeks inputs on trade issues faced with Japan
THE Department of Commerce (DoC), under the Union Commerce Ministry, has sought inputs from the industry on specific issues being faced in pharma trade with Japan.
1 min
December 11, 2025
Chronicle Pharmabiz
AIOCD asks traders to strictly comply with ban on 35 FDCs
THE All India Organisation of Chemists and Druggists (AIOCD) has issued an urgent internal circular to all its state and Union territory trade bodies, demanding immediate and strict compliance with the ban on 35 fixed dose combinations (FDCs).
3 mins
December 11, 2025
Chronicle Pharmabiz
US FDA approves Bristol Myers Squibb's Breyanzi
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.
2 mins
December 11, 2025
Chronicle Pharmabiz
CN Water presents AQU@Sense MB
CN Water is now combining core water-system expertise with digital assurance has launched AQU@Sense which delivers microbial test results in under 30 minutes, replacing traditional 5 to 7 days culture based methods.
1 min
December 11, 2025
Chronicle Pharmabiz
Pharma logistics sees policy push as key catalyst for growth
INDIAN pharma's logistics sector is getting major boost from emerging policy support.
2 mins
December 11, 2025
Chronicle Pharmabiz
Lack of financial aid, expertise mar MSME prospects to meet revised Sch M deadline
INDUSTRY experts have raised alarm that lack of financial assistance and guidance on technical expertise have marred pharma MSMEs’ prospects to comply with revised Schedule M guidelines of December 31, 2025.
2 mins
December 11, 2025
Listen
Translate
Change font size

